A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
France- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Residence Les Maisonnees, 10 Rue Du Champ Gaillard, 78300 Poissy, France
Centre Hospitalier Intercommunal De Poissy Saint Germain in Poissy, France specialises in clinical trials of conditions such as Perinatal depression, Relapsing multiple sclerosis, Secondary progressive multiple sclerosis, Progressive relapsing multiple sclerosis, and other specialisations. This site conducts important research.
The Centre Hospitalier Intercommunal De Poissy Saint Germain is conducting research aimed at reducing pregnancy‑related risks. A study evaluates whether routine use of aspirin early in gestation can lower the incidence of preterm preeclampsia among first‑time mothers who conceived through assisted reproductive technology.
This work supports improved maternal health and may inform guidelines for obstetric care in France.
Investigators are assessing the long‑term safety of the oral agent tolebrutinib in adults living with multiple sclerosis, including both relapsing and progressive forms. The trial monitors tolerability and potential adverse effects over an extended period.
Findings could expand therapeutic options for patients with chronic neuro‑inflammatory disease and guide clinicians across Europe.
The research programme also addresses broader clinical concerns by tracking adverse events and symptom patterns in participants from both obstetric and neurology studies, ensuring comprehensive safety surveillance.
This cross‑disciplinary approach enhances the centre’s capacity to protect participants and generate robust evidence for health policy.
Clinical trials currently enrolling participants at this site.
France
France
France
France
FranceGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.